Related references
Note: Only part of the references are listed.The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies
Mounica Reddy-Thootkur et al.
SCHIZOPHRENIA RESEARCH (2022)
Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis
Edward Millgate et al.
PSYCHOLOGICAL MEDICINE (2022)
Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naive Patients With Schizophrenia or Psychosis
Kirsten Borup Bojesen et al.
BIOLOGICAL PSYCHIATRY (2021)
A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia
Jennifer M. Coughlin et al.
MOLECULAR PSYCHIATRY (2021)
Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)
Alice Egerton et al.
SCHIZOPHRENIA BULLETIN (2021)
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
Grant McQueen et al.
SCHIZOPHRENIA BULLETIN (2021)
Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study
Edward Millgate et al.
BMJ OPEN (2021)
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level A Mega-analysis of Individual Participant-Level Data
Kate Merritt et al.
JAMA PSYCHIATRY (2021)
Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis A Systematic Review and Meta-analysis
Ana Catalan et al.
JAMA PSYCHIATRY (2021)
Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
Stephen J. Kaar et al.
NEUROPHARMACOLOGY (2020)
Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study
Ryosuke Tarumi et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
Robert A. McCutcheon et al.
WORLD PSYCHIATRY (2020)
Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia A Systematic Review and Meta-analysis
Katherine Beck et al.
JAMA NETWORK OPEN (2020)
Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study
Yusuke Iwata et al.
BIOLOGICAL PSYCHIATRY (2019)
Neuropsychological function at first episode in treatment-resistant psychosis: findings from the æSOP-10 study
Eugenia Kravariti et al.
PSYCHOLOGICAL MEDICINE (2019)
Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis
Anna M. Wang et al.
JAMA PSYCHIATRY (2019)
Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate
Kate Merritt et al.
NPJ SCHIZOPHRENIA (2019)
Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre H-1-MRS study (OPTiMiSE)
A. Egerton et al.
MOLECULAR PSYCHIATRY (2018)
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders A Randomized Clinical Trial
Daniel C. Javitt et al.
JAMA PSYCHIATRY (2018)
Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
Kirsten Borup Bojesen et al.
FRONTIERS IN PSYCHIATRY (2018)
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
Amy L. Gillespie et al.
BMC PSYCHIATRY (2017)
The Trouble With Quality Filtering Based on Relative Cramer-Rao Lower Bounds
Roland Kreis
MAGNETIC RESONANCE IN MEDICINE (2016)
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive
Elias Mouchlianitis et al.
SCHIZOPHRENIA BULLETIN (2016)
Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia
Laura M. Rowland et al.
JAMA PSYCHIATRY (2016)
Elevated brain lactate in schizophrenia: a 7T magnetic resonance spectroscopy study
L. M. Rowland et al.
TRANSLATIONAL PSYCHIATRY (2016)
Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
Meghan Elizabeth Goldstein et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials
Y. Iwata et al.
MOLECULAR PSYCHIATRY (2015)
Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia
Kara Dempster et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2015)
Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis
E. Bora et al.
ACTA PSYCHIATRICA SCANDINAVICA (2014)
Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
G. Desamericq et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Relationship Between Glycine Transporter I Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates
S. A. Castner et al.
NEUROPSYCHOPHARMACOLOGY (2014)
The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey
Donnie Eddins et al.
PSYCHOPHARMACOLOGY (2014)
Meta-analysis of cognitive performance in drug-naive patients with schizophrenia
Helena Fatouros-Bergman et al.
SCHIZOPHRENIA RESEARCH (2014)
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia A Randomized, Double-Blind, Proof-of-Concept Study
Daniel Umbricht et al.
JAMA PSYCHIATRY (2014)
Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia
Liv E. Falkenberg et al.
NEUROIMAGE-CLINICAL (2014)
A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation
Monica Aas et al.
FRONTIERS IN PSYCHIATRY (2014)
Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of H-1-MRS Studies
Anouk Marsman et al.
SCHIZOPHRENIA BULLETIN (2013)
In Vivo Measurements of Glutamate, GABA, and NAAG in Schizophrenia
Laura M. Rowland et al.
SCHIZOPHRENIA BULLETIN (2013)
Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis
Kate Merritt et al.
Frontiers in Psychiatry (2013)
Elevated Prefrontal Cortex γ-Aminobutyric Acid and Glutamate-Glutamine Levels in Schizophrenia Measured In Vivo With Proton Magnetic Resonance Spectroscopy
Lawrence S. Kegeles et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Cognitive Functioning in Prodromal Psychosis A Meta-analysis
Paolo Fusar-Poli et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
Bita Moghaddam et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia
Alice Egerton et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Capturing the Angel in Angel Dust: Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans
Bita Moghaddam et al.
SCHIZOPHRENIA BULLETIN (2012)
Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla
Juan R. Bustillo et al.
BIOLOGICAL PSYCHIATRY (2011)
Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia
Meredith A. Reid et al.
BIOLOGICAL PSYCHIATRY (2010)
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Guochuan E. Tsai et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Richard B. Mailman et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study
Yukihiko Shirayama et al.
NEUROIMAGE (2010)
With or Without U? The Appropriate Test for a U-Shaped Relationship
Jo Thori Lind et al.
OXFORD BULLETIN OF ECONOMICS AND STATISTICS (2010)
Neurocognition in First-Episode Schizophrenia: A Meta-Analytic Review
Raquelle I. Mesholam-Gately et al.
NEUROPSYCHOLOGY (2009)
Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis
Joseph Ventura et al.
SCHIZOPHRENIA RESEARCH (2009)
The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity
Keith H. Nuechterlein et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Regional variations and the effects of age and gender on glutamate concentrations in the human brain
Napapon Sailasuta et al.
MAGNETIC RESONANCE IMAGING (2008)
Neurochemical and structural correlates of executive dysfunction in schizophrenia
Nicolas Ruesch et al.
SCHIZOPHRENIA RESEARCH (2008)
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
Richard S. E. Keefe et al.
SCHIZOPHRENIA RESEARCH (2008)
Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy
Patricia Ohrmann et al.
SCHIZOPHRENIA RESEARCH (2008)
Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls
Sumie Leung et al.
PSYCHOPHARMACOLOGY (2008)
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study
Patricia Ohrmann et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2007)
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia - Is it a practice effect?
Terry E. Goldberg et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats
Nurith Amitai et al.
PSYCHOPHARMACOLOGY (2007)
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia
ND Woodward et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2005)
Dose response and dose equivalence of antipsychotics
JM Davis et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
RSE Keefe et al.
SCHIZOPHRENIA RESEARCH (2004)
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book
AL Mishara et al.
BIOLOGICAL PSYCHIATRY (2004)
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
DC Goff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Cognitive and emotional influences in anterior cingulate cortex
G Bush et al.
TRENDS IN COGNITIVE SCIENCES (2000)
Share Paper
